Business Daily Media

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory

BEIJING, CHINA - Media OutReach - 6 June 2022 - Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

The financing comprised a mix of new investors, including a large, diversified asset management firm on the US West Coast and BHR Partners, along with current investors, including Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. Insilico’s founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.

Capital raised in the round will further bolster Insilico’s financial position and fuel the growth of its advancing pipeline, including its lead program which is currently in a Phase I study, and continued development of its Pharma.AI platform. The proceeds will also fund ongoing global expansion and planned strategic initiatives, including a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement Insilico’s vast curated data assets.

“Despite unprecedented market conditions in the biotechnology sector, we raised this Series D round from several of the most reputable US-based and global investors,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “It is a testament to the strength of our end-to-end AI platform, which has been validated by many partners, and produced our first novel antifibrotic program discovered using AI and aging research, and designed using our generative AI chemistry engine. This unique program completed a first-in-human Phase 0 study in healthy volunteers and has entered Phase I clinical trials. We have also nominated seven preclinical candidates across a number of other disease indications since 2021. I am very excited about this progress and have decided to personally invest in this round.”

“The application of artificial intelligence and machine learning for drug discovery has incredible potential to transform the way new therapies are developed,” said Min Fang, Managing Director, Head of China Healthcare at Warburg Pincus. “For Insilico, 2022 was a year of incredible growth and progress. They have demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery. We’re delighted to continue to partner with the Insilico team and support a company that is at the forefront of this innovation.”

Since the previous round of financing, Insilico has developed a growing portfolio in frontier areas empowered by its proprietary AI platform. Seven programs in its internal pipeline have progressed to the IND-enabling stage, including a novel 3CL protease inhibitor for COVID-19 treatment, and two synthetic lethality programs targeting MAT2A and USP1 for oncology. It also successfully completed a Phase 0 microdose study and entered a Phase I clinical trial with its first internally developed program targeting fibrosis.

“With the power of cutting-edge AI platforms developed fully in house and validated by many global pharmaceutical companies and our innovative, highly parallel, fully distributed drug discovery model, we nominated seven preclinical candidates since I joined the company in 2021,” said Feng Ren, PhD, Insilico’s Chief Scientific Officer and Head of Global Research and Development. “I have 15 years of experience working in large pharmaceutical companies and CROs and I am impressed by the speed and quality of our discovery programs. We plan to continue expanding the breadth of the pipeline and enhance our AI and robotics capabilities globally. Our rapidly growing team is composed of talented and experienced scientists in drug discovery with diverse backgrounds and relentless passion for novelty and innovation, and fully committed to developing novel drugs with a sense of urgency for the waiting patients.”

Insilico has also expanded its collaborations with the pharmaceutical industry through co-development and software licensing deals with a number of major pharmaceutical companies. Since the launch of its PandaOmics™ and Chemistry42™ in late 2020, nine out of the top 20 pharmaceutical companies have licensed Insilico’s AI platforms. In 2022, Insilico signed a multi-asset partnership deal with Fosun Pharma and EQRX in January, and a drug discovery co-development deal with EQRx in March. Notably, Insilico achieved its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy in less than 40 days into the strategic collaboration with Fosun Pharma.




About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

#InsilicoMedicine #BCapitalGroup

News from Asia

Madar Saudi Arabia Recognized as One of the Best Places to Work for 2024

RIYADH, SAUDI ARABIA - Media OutReach Newswire - 31 October 2024 - Madar is proud to announce its certification as a Best Places to Work for 2024, a recognition that highlights the company's unwav...

AIM Vaccine’s 13-valent pneumonia conjugate vaccine obtained Production license

Application for drug marketing registration duly submitted Super heavyweight items are expected to drive performance soaring HONG KONG SAR - Media OutReach Newswire – 1 November 2024 - AIM Vaccin...

Light Show Illuminates the Liangma River

BEIJING, CHINA - Media OutReach Newswire - 31 October 2024 - During the recently launched 2024 Beijing Chaoyang International Light Festival, the Liangma River Cultural and Economic Belt, on the t...

426 Major Projects Accelerating in Ordos

ORDOS, CHINA – Media OutReach Newswire – 31 October 2024 - On October 28, nearly 20,000 builders fought on the front line at the site of the 2.6 million tons of coal-to-olefins and supporting 400...

VTEX and ChannelEngine Forge Powerful Alliance to Revolutionize the Ecommerce Landscape

SINGAPORE - Media OutReach Newswire - 4 March 2024 - VTEX (NYSE: VTEX), the global enterprise digital commerce platform, announced today its partnership with ChannelEngine, a leading global marke...

Siam Paragon Bangkok International Fashion Week 2024 Unveils the best of Thai and Asian Creativity And Reaffirms Siam Paragon As the Number One ‘Luxury Destination’

BANGKOK, THAILAND - Media OutReach Newswire - 1 November 2024 - Siam Paragon reaffirms its positioning as a leading 'global luxury destination' and the top-of-mind destination for both Thai and i...

EdgeProp announces winners of EdgeProp Excellence Awards 2024; City Developments, GuocoLand, SingHaiyi Group and UOL Group are Top Developers

City Developments, GuocoLand, SingHaiyi Group and UOL Group emerged as major winners with more than 9 awards each Lentor Mansion, Tembusu Grand and TMW Maxwell clinched 4 Exc...

Merck Announces Emerging Biotech Grant Program Winners

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market Merck experts to provide consultation and training in qualification, risk assess...

Ocean City to host International Lantern Design Contest and Festival

HANOI, VIETNAM- Media OutReach Newswire - 1 November 2024 - Vinhomes JSC and Sunny Vietnam Co. announce the launch of the Ocean International Lantern Contest and Festival. This event marks the fi...

Lee Kum Kee Garners Industry Cares Recognition Scheme 2024 ‘Grand Award’ from the Federation of Hong Kong Industries

HONG KONG SAR - Media OutReach Newswire - 1 November 2024 - On 26 September, Lee Kum Kee rejoiced as the recipient of the esteemed 'Grand Award', 'The Most Devoted Award' and 'The Most Innovative ...

PRAHRAN WAREHOUSE SNAPPED UP

A private local developer has bought a warehouse at 35-39 Clifton Street in Prahran, reflecting the  renewed appetite in the post-lockdown climate f...

Property

Rust: How to die and resurrect yourself

Rust is an open world survival game in which action / adventure and role-playing elements combine DayZ and Minecraft. You play in the middle of ...

Business Training

Unlock Your Dream Home With the Best Cowra Home Builders

Cowra is a charming small town in New South Wales, Australia. It is known for its rich agricultural and cultural heritage, and for its vibrant loc...

Property

It’s a tough market for renters – here’s how to make the most of your rental

Licensed real estate agent and proptech expert, Scott Shepherd from PropertyMe shares his top tips from over two decades in the industry The rate...

Property

Basic Dropshipping Business Tips To Remember

During the pandemic one of the businesses which many people looked to get involved with was dropshipping, a great option if you know what you are do...

Business Training

How To Choose The Best Building Inspection Company?

You've found the house of your dreams at long last. The pricing is fair, and the funds are in good standing. Is the property, on the other hand, a...

Property